학술논문
A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States.
Document Type
Article
Author
Source
EJHaem; Feb2023, Vol. 4 Issue 1, p135-144, 10p
Subject
Language